Concanavalin A conjugated biodegradable nanoparticles for oral insulin delivery
Source abstract
Abstract
Major research issues in oral protein delivery include the stabilization of protein in delivery devices which could increase its oral bioavailability. The study deals with development of oral insulin delivery system utilizing biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles and modifying its surface with Concanavalin A to increase lymphatic uptake. Surface-modified PLGA nanoparticles were characterized for conjugation efficiency of ligand, shape and surface morphology, particle size, zeta potential, polydispersity index, entrapment efficiency, and in vitro drug release. Stability of insulin in the developed formulation was confirmed by SDS-PAGE, and integrity of entrapped insulin was assessed using circular dichroism spectrum. Ex vivo study was performed on Wistar rats, which exhibited the higher intestinal uptake of Con A conjugated nanoparticles. In vivo study performed on streptozotocin-induced diabetic rats which indicate that a surface-modified nanoparticle reduces blood glucose level effectively within 4 h of its oral administration. In conclusion, the present work resulted in successful production of Con A NPs bearing insulin with sustained release profile, and better absorption and stability. The Con A NPs showed high insulin uptake, due to its relative high affinity for non-reducing carbohydrate residues i.e., fucose present on M cells and have the potential for oral insulin delivery in effective management of Type 1 diabetes condition.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Diabetes Management and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Barr WH, Riegelman S (1970) Intestinal drug absorption and metabolism: comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption. J Pharm Sci 59:154–16310.1002/jps.2600590204 ↗
2. Bies C, Lehr CM, Woodley JF (2004) Lectin-mediated drug targeting: history and applications. Adv Drug Del Rev 56:425–43510.1016/j.addr.2003.10.030 ↗
3. Cevc G (1996) Transferosomes, liposomes and other liquid suspension on the skin: permeation enhancement vesicle penetration and transdermal drug delivery. Crit Rev Ther Drug Carr Syst 13:257–38810.1615/CritRevTherDrugCarrierSyst.v13.i3-4.30 ↗
4. Chalasani KB, Russell Jones GJ, Yandrapu SK, Diwan PV, Jain SK (2007) Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Cont Rel 122(2):141–15010.1016/j.jconrel.2007.05.019 ↗
5. Chen XJ, Zhu JB, Wang GJ, Zhou MX, Xin FM, Zhang N, Wang CX, Xu YN (2002) Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. Acta Pharmacol Sin 23:467–470
6. Clark MA, Hirst BH, Jepson MA (2000) Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Del Rev 43:207–22310.1016/S0169-409X(00)00070-3 ↗
7. Cui FD, Tao AJ, Cun DM, Zhang LQ, Shi K (2007) Preparation of Insulin Loaded PLGA-Hp55 Nanoparticles for Oral Delivery. J Pharma Sci 96(2):421–42710.1002/jps.20750 ↗
8. Das N, Madan P, Lin S (2010) Development and in vitro evaluation of insulin-loaded buccal Pluronic F-127 gels. Pharm Dev Technol 15(2):192–20810.3109/10837450903085442 ↗
9. David JB, Alan WB (2004) Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. Adv Drug Del Rev 56:721–72610.1016/j.addr.2003.10.036 ↗
10. Desai MP, Labhasetwar V, Amidon GL, Levy RJ (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13:1838–184510.1023/A:1016085108889 ↗
11. Desai TR, Hancock REW, Finlay WH (2002) A facile method of delivery of liposomes by nebulization. J Cont Rel 84:69–7810.1016/S0168-3659(02)00264-X ↗
12. Deutel B, Griendl M, Thaurer M, Bernkop-Schnurch A (2008) Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules 9(1):278–28510.1021/bm700916h ↗
13. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles. Proc Natl Acad Sci 105:17356–1736110.1073/pnas.0809154105 ↗
14. Diebolda Y, Jarrin M, Saez V, Carvalho ELS, Orea M, Calonge M, Seijo B, Alonso MJ (2007) Ocular drug delivery by liposome–chitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553–156410.1016/j.biomaterials.2006.11.028 ↗
15. Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, Nokhodchi A (2009) Pharmaceutics, preformulation and drug delivery: a novel approach to prepare insulin-loaded Poly(Lactic-Co-Glycolic Acid) microcapsules and the protein stability study. J Pharma Sci 98:510.1002/jps.21544 ↗
16. Ezpeleta I, Arangoa MA, Irache JM, Stainmesse S, Chabenat C, Popineau Y, Orecchioni AM (1999) Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int J Pharm 191:25–3210.1016/S0378-5173(99)00232-X ↗
17. Granger DN, Mortillaro NA, Kvietys PR, Rutili G, Parker JC, Taylor AE (1980) Role of the interstitial matrix during intestinal volume absorption. Am J Physiol 238(3):G183–G189
18. Harmony JA, Cordes EH (1975) Native human plasma low density lipoprotein (LDL) interacts with Concanavalin A but not with ricin. J Biol Chem 250(22):8614–861710.1016/S0021-9258(19)40714-X ↗
19. Irache JM, Durrer C, Duchêne D, Ponchel G (1996) Bioadhesion of lectin-latex conjugate to rat intestinal mucosa. Pharm Res 13:1716–171910.1023/A:1016405126656 ↗
20. Jain A, Jain SK (2008) PEGylation: an approach for Drug Delivery. Crit rev Ther Drug Carr Syst 25(5):403–44410.1615/CritRevTherDrugCarrierSyst.v25.i5.10 ↗
21. Johannson F, Hjertberg E, Eirefelt S, Tronde A, Bengtsson UH (2002) Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci 17:63–7110.1016/S0928-0987(02)00133-1 ↗
22. Joshi SR, Parikh RM, Das AK (2007) Insulin: history, biochemistry, physiology and pharmacology. Suppl JAPI 55–58
23. Kadiyala I, Loo Y, Roy K, Rice J, Leong KW (2009) Transport of chitosan–DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur J Pharm Sci 39(1–3):103–109
24. Keegan ME, Royce SM, Fahm T, Saltzman WM (2006) In vitro evaluation of biodegradable microspheres with surface-bound ligands. J Cont Rel 110:574–58010.1016/j.jconrel.2005.11.004 ↗
25. Kim BY, Jeong JH, Park K, Kim JD (2005) Bioadhesive interaction and hypoglycemic effect of insulin-loaded lectin-microparticle conjugates in oral insulin delivery system. J Cont Rel 102:525–53810.1016/j.jconrel.2004.10.032 ↗
26. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchii H, Maincent P, Kawashima Y, Lehr CM (2001) Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299:775–78110.1016/S0022-3565(24)29290-9 ↗
27. Lehr CM, Bouwstra JA, Kok W, Noach ABJ, de Boer AG, Junginger HE (1992) Bioadhesion by means of specific binding of tomato lectin. Pharm Res 9:547–55310.1023/A:1015804816582 ↗
28. Mahato RI, Narang AS, Thomas L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carr Syst 20(2&3):153–21410.1615/CritRevTherDrugCarrierSyst.v20.i23.30 ↗
29. Mo Y, Lim LY (2005) Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Cont Rel 107:30–4210.1016/j.jconrel.2004.06.024 ↗
30. Montisci MJ, Giovannuci G, Duchêne D, Ponchel G (2001) Covalent coupling of asparagus pea and tomato lectins to poly (lactide) microspheres. Int J Pharm 215:153–16110.1016/S0378-5173(00)00678-5 ↗
31. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK (2008) Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharma Biopharma 68(3):513–525
32. Mrisko-Liversidge E, McGurk SL, Liversidge GG (2004) Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn–Insulin. Pharm Res 21(9):1545–155310.1023/B:PHAM.0000041446.14569.e2 ↗
33. Ning M, Guo Y, Pan H, Yu H, Gu Z (2005) Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: studies in rats. Drug Del 12(6):399–40710.1080/10717540590968891 ↗
34. O’Driscoll CM (2002) Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15(5):405–41510.1016/S0928-0987(02)00051-9 ↗
35. Owens DR (2002) New horizons–alternative routes for insulin therapy. Nat Rev Drug Disc 1:529–54010.1038/nrd836 ↗
36. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta N, Mehta A, Vyas SP (2009) Effect of lipid core material on characterisitics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5(2):184–19110.1016/j.nano.2008.08.003 ↗
37. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K (2001) Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 221:143–15210.1016/S0378-5173(01)00676-7 ↗
38. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid endo-lysosomal escape of poly (dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16:1217–122610.1096/fj.02-0088com ↗
39. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2:8–2110.1016/j.nano.2005.12.003 ↗
40. Portero A, Teijeiro-Osorio T, Alonso MJ, Remuñán-López C (2007) Development of chitosan sponges for buccal administration of insulin. Carbohydr Polym 68:617–62510.1016/j.carbpol.2006.07.028 ↗
41. Pringels E, Callens C, Vervaet C, Dumont F, Slegers G, Foreman P, Remon JP (2006) Influence of deposition and spray pattern of nasal powders on insulin bioavailability. Int J Pharm 310:1–710.1016/j.ijpharm.2005.10.049 ↗
42. Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Cont Rel 116:1–2710.1016/j.jconrel.2006.08.013 ↗
43. Russell-Jones GJ, Veitch H, Arthur L (1999) Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int J Pharm 190:165–17410.1016/S0378-5173(99)00254-9 ↗
44. Sarmento B, Ferreira D, Veiga F, Ribeiro A (2006) Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym 66:1–710.1016/j.carbpol.2006.02.008 ↗
45. Shaikh IM, Jadhav KR, Ganga S, Kadam VJ, Pisal SS (2005) Advanced approaches in insulin delivery. Curr Pharma Biotech 6:387–39510.2174/138920105774370599 ↗
46. Socha M, Sapin A, Damgé C, Maincent P (2009) Influence of polymers ratio on insulin-loaded nanoparticles based on poly-epsilon-caprolactone and Eudragit RS for oral administration. Drug Del 16(8):430–43610.3109/10717540903223442 ↗
47. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, Sung HW (2010) Enteric-coated capsules filled with freeze-dried chitosan/poly(γ-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31(12):3384–339410.1016/j.biomaterials.2010.01.042 ↗
48. Souder JC, Ellenbogen WC (1995) Control of d-amphetamine sulphate sustained release capsule. Drug Standards 26:77–79
49. Srinivasan R, Jain SK (1998) Insulin delivery through the ocular route. Drug Del 5(1):53–5510.3109/10717549809052027 ↗
50. Stevanoviae M, Saviæ J, Jordoviae B, Uskokoviae D (2007) Fabrication, in vitro degradation and the release behaviours of poly(dl-lactide-co-glycolide) nanospheres containing ascorbic acid. Colloids Surf B Biointerfaces 59:215–22310.1016/j.colsurfb.2007.05.011 ↗
51. Stolnik S, Garnett MC, Davies MC et al (1995) The colloidal properties of surfactant-free biodegradable nanospheres from poly (b-malic acid-co-benzyl malate) and poly (lactic acid-co-glycolide). Colloids Surf 97:235–24510.1016/0927-7757(95)03081-N ↗
52. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270–27510.1023/A:1011922819926 ↗
53. Tripathi KD (2003) Insulin, oral hypoglycaemic drugs and glucagon. Essentials of medical pharmacology, 5th edn. Jaypee Brothers, Medical Publisher’s (P) Ltd. New Delhi, p 235–237
54. Verger ML, Fluckiger L, Kim Y, Hoffman M, Maincent P (1998) Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 46:137–14310.1016/S0939-6411(98)00015-0 ↗
55. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P (2001) Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm 51:93–10910.1016/S0939-6411(00)00144-2 ↗
56. Wood KM, Stone GM, Peppas NA (2008) Wheat germ agglutinin functionalized complexation hydrogels for oral insulin delivery. Biomacromolecules 9(4):1293–129810.1021/bm701274p ↗
57. Wua ZM, Zhoub L, Guoa XD, Jianga W, Linga L, Qiana Y, Luoc KQ, Zhanga LJ (2012) HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharma 425:1–810.1016/j.ijpharm.2011.12.055 ↗
58. Xiongliang X, Yao F, Haiyan H, Yourong D, Zhirong Z (2006) Quantitative determination of insulin entrapment efficiency in triblock copolymeric nanoparticles by high-performance liquid chromatography. J Pharm Biomed Anal 41:266–27310.1016/j.jpba.2005.10.016 ↗
59. Xu BH, Huang KX, Zhu YS, Gao QH, Wu QZ, Tian WQ et al (2002) Hypoglycaemic effect of a novel insulin buccal formulation on rabbits. Pharmacol Res 46:459–46710.1016/S1043661802002049 ↗
60. Xuan B, McClellan DA, Moore R, Chiou GCY (2005) Alternative delivery of insulin via eye drops. Diabetes Tech Ther 7(5):695–69810.1089/dia.2005.7.695 ↗
61. Yin YS, Chen DW, Qiao MX, Lu Z, Hu HY (2006) Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Cont Rel 116:337–34510.1016/j.jconrel.2006.09.015 ↗
62. Yoo HS, Park TG (2004) Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Cont Rel 96:273–28310.1016/j.jconrel.2004.02.003 ↗
63. Zhu X, Su M, Tang S, Wang L, Liang X, Meng F, Hong Y, Xu Z (2012) Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery. Mol Vis 18:1973–1982